Oncopeptides AB (publ) (STO:ONCO)

Market Cap	748.58M +157.3%
Revenue (ttm)	62.47M +130.7%
Net Income	-267.84M
EPS	-1.24
Shares Out	272.71M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	865,903
Average Volume	2,316,379
Open	2.740
Previous Close	2.745
Day's Range	2.715 - 2.860
52-Week Range	1.100 - 6.960
Beta	-1.70
RSI	29.95
Earnings Date	Feb 19, 2026

About Oncopeptides AB

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hyd...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 75
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ONCO

Financial Performance

In 2024, Oncopeptides AB's revenue was 31.65 million, a decrease of -10.14% compared to the previous year's 35.22 million. Losses were -284.61 million, 14.2% more than in 2023.